Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC 1 receptor
British Journal of Pharmacology · 2024-08 · 181 (15) · 2655-2675
DOI: 10.1111/bph.16376 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 14.04.2024. Verfasst von Zoe Tasma und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, The University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Spinal Cord, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I, Pituitary Adenylate Cyclase-Activating Polypeptide, Vasoactive Intestinal Peptide. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Royal Society Te Apārangi, Health Research Council of New Zealand.
Abstract (Originalsprache)
Background and Purpose The spinal cord is a key structure involved in the transmission and modulation of pain. Pituitary adenylate cyclase‐activating peptide (PACAP) and vasoactive intestinal peptide (VIP), are expressed in the spinal cord. These peptides activate G protein‐coupled receptors (PAC 1 , VPAC 1 and VPAC 2 ) that could provide targets for the development of novel pain treatments. However, it is not clear which of these receptors are expressed within the spinal cord and how these receptors signal. Experimental Approach Dissociated rat spinal cord cultures were used to examine agonist and antagonist receptor pharmacology. Signalling profiles were determined for five signalling pathways. The expression of different PACAP and VIP receptors was then investigated in mouse, rat and human spinal cords using immunoblotting and immunofluorescence. Key Results PACAP, but not VIP, potently stimulated cAMP, IP 1 accumulation and ERK and cAMP response element‐binding protein (CREB) but not Akt phosphorylation in spinal cord cultures. Signalling was antagonised by M65 and PACAP 6–38 . PACAP‐27 was more effectively antagonised than either PACAP‐38 or VIP. The patterns of PAC 1 and VPAC 2 receptor‐like immunoreactivity appeared to be distinct in the spinal cord. Conclusions and Implications The pharmacological profile in the spinal cord suggested that a PAC 1 receptor is the major functional receptor subtype present and thus likely mediates the nociceptive effects of the PACAP family of peptides in the spinal cord. However, the potential expression of both PAC 1 and VPAC 2 receptors in the spinal cord highlights that these receptors may play differential roles and are both possible therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Sciences, The University of Auckland, Auckland, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.
- Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Odontology, Panum Institute, Faculty of Health, University of Copenhagen, Copenhagen, Denmark.
- Department of Anatomy and Medical Imaging and Centre for Brain Research, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand.
- Department of Pharmacology and Toxicology, The University of Otago, Dunedin, New Zealand.
ORCID-Profile: Zoe Tasma, Debbie L Hay, Christopher S Walker
Förderung
- Royal Society Te Apārangi
- Health Research Council of New Zealand
Zitieren
APA
Tasma, Z., Rees, T. A., Guo, S., Tan, S., O'Carroll, S. J., Faull, R. L. M., Curtis, M. A., Christensen, S. L., Hay, D. L., & Walker, C. S. (2024). Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC 1 receptor. British Journal of Pharmacology, 181(15), 2655-2675. https://doi.org/10.1111/bph.16376
Vancouver
Tasma Z, Rees TA, Guo S, Tan S, O'Carroll SJ, Faull RLM, et al. Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC 1 receptor. British Journal of Pharmacology. 2024;181(15):2655-2675. doi:10.1111/bph.16376
BibTeX
@article{Tasma2024,
author = {Tasma, Zoe and Rees, Tayla A and Guo, Song and Tan, Sheryl and O'Carroll, Simon J and Faull, Richard L M and Curtis, Maurice A and Christensen, Sarah L and Hay, Debbie L and Walker, Christopher S},
title = {Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC 1 receptor},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {15},
pages = {2655--2675},
doi = {10.1111/bph.16376}
}
EUVIMED